UY39979A - Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas - Google Patents

Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas

Info

Publication number
UY39979A
UY39979A UY0001039979A UY39979A UY39979A UY 39979 A UY39979 A UY 39979A UY 0001039979 A UY0001039979 A UY 0001039979A UY 39979 A UY39979 A UY 39979A UY 39979 A UY39979 A UY 39979A
Authority
UY
Uruguay
Prior art keywords
pyrrolo
triazines
preparation
treatment
triazine compounds
Prior art date
Application number
UY0001039979A
Other languages
English (en)
Spanish (es)
Inventor
Gopi Kumar Mittapalli
Kc Sunil Kumar
Chi Ching Mak
Brian Joseph Hofilena
Joseph Timothy Marakovits
Lewis Daniel Turner
Brian Walter Eastman
Ramkrishna Reddy Vakiti
Original Assignee
Biosplice Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosplice Therapeutics Inc filed Critical Biosplice Therapeutics Inc
Publication of UY39979A publication Critical patent/UY39979A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY0001039979A 2021-10-12 2022-10-12 Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas UY39979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254733P 2021-10-12 2021-10-12
US202263347757P 2022-06-01 2022-06-01

Publications (1)

Publication Number Publication Date
UY39979A true UY39979A (es) 2023-04-14

Family

ID=84330173

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039979A UY39979A (es) 2021-10-12 2022-10-12 Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas

Country Status (12)

Country Link
US (2) US12134625B2 (enExample)
EP (1) EP4415816B1 (enExample)
JP (1) JP2024539620A (enExample)
KR (1) KR20240089275A (enExample)
AU (1) AU2022367222A1 (enExample)
CA (1) CA3234831A1 (enExample)
IL (1) IL312157A (enExample)
MX (1) MX2024004552A (enExample)
PY (1) PY2289204A (enExample)
TW (1) TW202322800A (enExample)
UY (1) UY39979A (enExample)
WO (1) WO2023064366A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3249870A1 (en) * 2022-01-25 2023-08-03 Kinnate Biopharma Inc. CDK4/6 KINASE INHIBITORS
EP4611890A1 (en) * 2022-11-03 2025-09-10 BioSplice Therapeutics, Inc. 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
WO2024211797A1 (en) * 2023-04-07 2024-10-10 Biosplice Therapeutics, Inc. Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
CN119019402A (zh) * 2023-05-24 2024-11-26 中国科学院上海有机化学研究所 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途
WO2025024707A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cdk2/4/6 kinase
US20250206746A1 (en) * 2023-12-22 2025-06-26 Biosplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
US10730842B2 (en) * 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
RU2020115154A (ru) * 2017-10-10 2021-11-15 Сирос Фармасьютикалз, Инк. Производные пирролотриазина и способы ингибирования киназ там
EP3759072A4 (en) 2018-03-01 2021-11-03 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM
US12528810B2 (en) * 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
EP3813826A4 (en) 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR
WO2020081689A1 (en) 2018-10-16 2020-04-23 Dana-Farber Cancer Institute, Inc. Azaindole inhibitors of wild-type and mutant forms of lrrk2
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2021257863A1 (en) * 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
AU2021313150A1 (en) 2020-07-20 2023-03-16 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
PY2289206A (es) 2021-10-12 2023-11-09 Biosplice Therapeutics Inc 7h-pirrolo[2,3-d] pirimidinas y preparación y usos de las mismas
WO2023064349A1 (en) 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
EP4543886A1 (en) 2022-06-23 2025-04-30 BioSplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof

Also Published As

Publication number Publication date
US20230312605A1 (en) 2023-10-05
PY2289204A (es) 2023-12-05
US12134625B2 (en) 2024-11-05
KR20240089275A (ko) 2024-06-20
TW202322800A (zh) 2023-06-16
IL312157A (en) 2024-06-01
JP2024539620A (ja) 2024-10-29
EP4415816B1 (en) 2026-03-18
US20250171466A1 (en) 2025-05-29
AU2022367222A1 (en) 2024-05-02
EP4415816A1 (en) 2024-08-21
CA3234831A1 (en) 2023-04-20
MX2024004552A (es) 2024-06-04
WO2023064366A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
UY39979A (es) Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas
UY39978A (es) 7h-pirrolo[2,3-d]pirimidinas y preparación y usos de las mismas
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
CO2022008243A2 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
GEAP202316298A (en) Highly active compounds against covid-19
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
MX2024015663A (es) 4-alcoxipirrolo[2,1-f][1,2,4]triazinas y preparación y uso de las mismas
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
SA98190487B1 (ar) مركبات ثلاثي 3.2.1- ازولو ]4،5- D [ بيريميدين1,2,3-triazolo[4,5-D] pyrimidines حديثه واستخداماتها كعقاقير وطرق لتحضيرها
AR048912A1 (es) Inmunoglobulinas anti-nogo
CO6300934A2 (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR0312398A (pt) Derivado de 1,3-difenilprop-2-en-1-ona substituìdo, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituìdo
ES2087639T3 (es) Nucleosidos terapeuticos.
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
MX2025005198A (es) 4-aminopirrolo[2,1-f][1,2,4]triazinas y preparacion y usos de estas
EA202092002A1 (ru) 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
EA202193223A1 (ru) Другие гетероароматические соединения, действующие против рсв
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
EA202091835A1 (ru) Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
EA202092439A1 (ru) Гетероароматические соединения, обладающие активностью против rsv